Dashboard
Manage Tickers

LLY ELI LILLY & Co

NYSE lilly.com


$ 803.08 $ -16.55 (-2.02 %)    

Friday, 17-Oct-2025 19:58:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 802.83
$ 787.39
$ 803.00 x 10
$ 805.00 x 11
$ 783.85 - $ 804.44
$ 622.41 - $ 931.66
3,982,950
na
722.39B
$ 0.60
$ 52.35
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-19-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 04-30-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 04-27-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 02-23-2022 12-31-2021 10-K
16 10-27-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-17-2021 12-31-2020 10-K
20 10-28-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-01-2020 03-31-2020 10-Q
23 02-19-2020 12-31-2019 10-K
24 10-25-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-19-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 07-25-2018 06-30-2018 10-Q
30 04-27-2018 03-31-2018 10-Q
31 02-20-2018 12-31-2017 10-K
32 10-27-2017 09-30-2017 10-Q
33 07-28-2017 06-30-2017 10-Q
34 05-01-2017 03-31-2017 10-Q
35 02-21-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 07-28-2016 06-30-2016 10-Q
38 04-29-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 10-30-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

trumps-weight-loss-drug-push-may-put-these-etfs-on-a-diet
Trump's Weight-Loss Drug Push May Put Thes...
10/17/2025 20:13:54

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

trump-induced-volatility-aside-novo-trades-cheap-while-patents-protect-its-profits-until-2032
Trump-Induced Volatility Aside, Novo Trade...
10/17/2025 18:33:22

Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused s...

eli-lilly-shares-are-trading-lower-friday-whats-going-on
Eli Lilly Shares Are Trading Lower Friday:...
10/17/2025 14:44:36

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss ...

novo-vs-lilly-vs-pfizer-who-wins-if-trump-slashes-the-price-of-weight-loss-drugs
Novo Vs. Lilly Vs. Pfizer: Who Wins If Tru...
10/17/2025 14:19:58

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential imp...

eli-lilly-releases-phase-3-monarche-trial-results-showing-that-two-years-of-verzenio-plus-endocrine-therapy-reduced-the-risk-of-death-by-158-compared-to-endocrine-therapy-alone-and-delivered-sustained-improvements-in-invasive-disease-free-and-distant-relapse-free-survival-for-patients-with-hr-her2--high-risk-early-breast-cancer
Eli Lilly Releases Phase 3 monarchE Trial ...
10/17/2025 12:05:45

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvan...

eli-lilly-novo-nordisk-hims--hers-health-shares-move-lower-after-trump-calls-out-fat-loss-drugs
Eli Lilly, Novo Nordisk, Hims & Hers Healt...
10/16/2025 21:24:18

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-lo...

Core News & Articles
President Trump Says I Think The Fat-Loss...
10/16/2025 20:33:25

https://www.youtube.com/watch?v=xagrobF4q1k 

guggenheim-reiterates-buy-on-eli-lilly-maintains-948-price-target
Guggenheim Reiterates Buy on Eli Lilly, Ma...
10/16/2025 12:57:43

Guggenheim analyst Seamus Fernandez reiterates Eli Lilly (NYSE:LLY) with a Buy and maintains $948 price target.

Core News & Articles
Eli Lilly's Oral Weight Loss Drug Shows Su...
10/15/2025 17:24:50

Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 ...

eli-lillys-orforglipron-meets-all-endpoints-in-achieve-2-and-achieve-5-phase-3-trials-demonstrates-significant-a1c-reduction-and-weight-loss-in-type-2-diabetes
Eli Lilly's Orforglipron Meets All Endpoin...
10/15/2025 10:49:19

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpointIn ACHIEV...

Core News & Articles
Recent Filing Shows That Sen. John Boozman...
10/13/2025 15:00:28

healthcare-opportunities-and-risks-collide-for-direxions-eli-lilly-focused-elil-elis-etfs
Healthcare Opportunities And Risks Collide...
10/13/2025 14:10:07

eli-lilly-to-support-whos-international-dementia-action-plan-under-signed-collaboration
Eli Lilly To Support WHO's International D...
10/13/2025 12:32:24

BERLIN, Oct. 13, 2025 /PRNewswire/ -- The WHO Foundation and Lilly have announced a collaboration to financially support the ai...

eli-lilly-to-present-new-data-across-oncology-portfolio-at-esmo-2025-highlighting-verzenio-and-emerging-cancer-therapies
Eli Lilly to Present New Data Across Oncol...
10/13/2025 10:47:43

Eli Lilly and Company (NYSE:LLY) today announced that new data from across its oncology portfolio and pipeline will be presente...

smart-money-is-betting-big-in-lly-options
Smart Money Is Betting Big In LLY Options
10/10/2025 20:01:08

bill-gates-and-paho-push-to-make-weight-loss-drugs-accessible-in-low-income-nations
Bill Gates And PAHO Push To Make Weight-Lo...
10/10/2025 17:58:32

Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.

direxions-qqqu-qqqd-etfs-foster-a-diversified-approach-to-magnificent-7-speculation
Direxion's QQQU, QQQD ETFs Foster A Divers...
10/09/2025 16:57:35

Core News & Articles
Recent Filing Shows That Rep. David Taylor...
10/08/2025 15:00:39

eli-lilly-to-rally-more-than-12-here-are-10-top-analyst-forecasts-for-wednesday
Eli Lilly To Rally More Than 12%? Here Are...
10/08/2025 14:04:25

guggenheim-maintains-buy-on-eli-lilly-raises-price-target-to-948
Guggenheim Maintains Buy on Eli Lilly, Rai...
10/08/2025 12:38:44

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $875 to $948.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION